Abstract 1411: Utilizing 7-azaindoles, 2,7-diazaindoles, and 1H-pyrazoles as core structures for novel cancer chemosensitizers
Authors: Gorecki Lukas , Muthna Darina , Merdita Sara , Andrs Martin , Kucera Tomas , Kobrlova Tereza , Rezacova Martina , Korabecny Jan 
Published: June 2022

Abstract
A quickly developing chemoresistance is the hallmark of the standard treatment failure and the poor patient prognosis. Resistance is often connected to the overexpression of the specific kinases that are involved in DNA damage response. Contrary, their inhibition could lead to augmented cancer cell sensitization to conventional approach. Among them, ataxia-telangiectasia and Rad3-related kinase (ATR), the major replication stress responder, is one of the most attractive target. Within this study our aim was to find novel chemosensitizing agents for the cancer treatment employment. Inspired by clinical candidates targeting ATR, we designed and prepared large library of 40 novel compounds utilizing 7-azaindoles, 2,7-diazaindoles, and 1H-pyrazoles as core structures. Initially, our presumption to have ATR inhibitors were confirmed by molecular dynamic study. All the compounds alone or in combination with cisplatin were screened against panel of nine cancer cell lines and one healthy cell line. The results were compared with well-known ATR inhibitor VE-821. Several compounds significantly inhibit the cell viability and some were able to potentiate cisplatin effect. From structure-activity relationship point of view, 7-azaindoles were the most cytotoxic compounds when substituted in position 3 and 5. Contrary, 2,7-diazaindoles expressed the most potent chemosensitizing capabilities. 1H-Pyrazoles were the least potent compounds within this screen. Interestingly, the status of tumor suppressor protein p53 (defect in G1) did not significantly influence chemosensitization or cytotoxic effect. Three highlighted compounds 3, 22, and 29 were selected for Broad oncology panel screening containing 104 kinases which could be potentially targeted. Only compound 29, the 2,7-diazaindole representative, showed ATR inhibitory efficacy with the IC50 around 10 µM. In contrast, the compound 22, 7-azaindole and the most cytotoxic one, expressed the multi-kinase activity with the substantial inhibitory capability against vascular endothelial growth factor receptor 3 protein (VEGFR-3). VEGFR-3 is also very attractive anticancer target with several inhibitors already approved. Finally, several compounds showed chemosensitizing potencies for temozolomide against secondary astrocytoma cell line. In overall, we showed that both, 7-azaindoles, and 2,7-diazaindoles, could be effectively utilized as novel anticancer agents. Whereas 2,7-diazaindoles could become efficient ATR inhibitors, 7-azaindoles have potential as antiangiogenics, VEGFR-3 inhibitors. Besides, both structures could be used for a glioblastoma treatment as temozolomide sensitizers. More research is currently ongoing to fully exploit potential of these compounds.
Citation Format: Lukas Gorecki, Darina Muthna, Sara Merdita, Martin Andrs, Tomas Kucera, Tereza Kobrlova, Martina Rezacova, Jan Korabecny. Utilizing 7-azaindoles, 2,7-diazaindoles, and 1H-pyrazoles as core structures for novel cancer chemosensitizers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1411.